Below are the financial statements of Biogen, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | — | — | — |
| Product revenue, net | 7,213.5a | 7,246.7a | 7,987.8a |
| Revenue from anti-CD20 therapeutic programs | 1,749.9a | 1,689.6a | 1,700.5a |
| Alzheimer's collaboration revenue | 59.9a | 0a | 0a |
| Contract manufacturing, royalty and other revenue | 652.6a | 899.3a | 485.1a |
| Total revenue | 9,675.9a | 9,835.6a | 10,173.4a |
| Cost and expense | — | — | — |
| Cost of sales, excluding amortization and impairment of acquired intangible assets | -2,310.4a | -2,533.4a | -2,278.3a |
| Research and development | -2,041.8a | -2,462a | -2,231.1a |
| Selling, general and administrative | -2,403.7a | -2,549.7a | -2,403.6a |
| Amortization and impairment of acquired intangible assets | -446.7a | -240.6a | -365.9a |
| Collaboration profit sharing/(loss reimbursement) | 254.4a | 218.8a | -7.4a |
| (Gain) loss on fair value remeasurement of contingent consideration | 27.7a | 0a | -209.1a |
| Restructuring charges | -30.2a | -218.8a | -131.1a |
| Gain on sale of priority review voucher, net | -88.6a | 0a | 0a |
| Gain on sale of building, net | 0a | 0a | -503.7a |
| Other (income) expense, net | 343.6a | 315.5a | -108.2a |
| Total cost and expense | -7,769.9a | -8,538.8a | -6,581.6a |
| Income before income tax (benefit) expense and equity in (income) loss of investee, net of tax | 1,906a | 1,296.8a | 3,591.8a |
| Income tax (benefit) expense | -273.8a | -135.3a | -632.8a |
| Equity in (income) loss of investee, net of tax | 0a | 0a | -2.6a |
| Net income | 1,632.2a | 1,161.5a | 2,961.6a |
| Net income (loss) attributable to noncontrolling interests, net of tax | 0a | 0.4a | -85.3a |
| Net income attributable to Biogen Inc. | 1,632.2a | 1,161.1a | 3,046.9a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.